News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Phenomix Corporation Announces PHX1149 Phase 2b Clinical Trial Results for Type 2 Diabetes
May 19, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation announced today that PHX1149, a dipeptidyl peptidase-4 (DPP-4) inhibitor, demonstrated positive results in a Phase 2b clinical trial for the treatment of Type 2 diabetes.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phenomix Corporation
MORE ON THIS TOPIC
Breast cancer
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
March 9, 2026
·
2 min read
·
Annalee Armstrong
Drug Development
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations
March 9, 2026
·
3 min read
·
Heather McKenzie
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
March 9, 2026
·
2 min read
·
Tristan Manalac
Weight loss
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
March 6, 2026
·
3 min read
·
Tristan Manalac
